Americans’ anxiety impacted by the ongoing pandemic, yet 1 in 5 say they won’t seek treatment according to the GeneSight^® Mental Health Monitor nationwide survey

SALT LAKE CITY, October 11, 2021– Many Americans are experiencing anxiety symptoms as a result of the pandemic. Yet, one in five say they won’t seek treatment for mental health conditions and others say they won’t get help until these symptoms take a toll in their lives.

Nearly half (46%) of all respondents rated their anxiety symptoms as moderate to severe over the past six months, according to the GeneSight^®Mental Health Monitor from Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine.

Of those surveyed who are diagnosed with anxiety, the numbers are even worse – 86% rated their anxiety symptoms as moderate to severe over the past six months. While the pandemic is only 18 months old, more than half of those diagnosed with anxiety say they lived with symptoms for years or decades before seeking treatment.

For those who haven’t sought treatment but are concerned they may be suffering from anxiety, only 36% are planning to seek treatment. When asked what it would take to get help for their anxiety, 47% said a debilitating panic attack. Additional reasons included not being able to leave their homes (34%), sleep issues (31%), an unshakeable feeling of dread (30%) and a negative impact to relationships (30%).

“Imagine waiting until you lose your hearing to treat an ear infection. Patients who are experiencing anxiety symptoms shouldn’t wait to seek treatment,” said Robin Miller, Internist, MD, MHS, owner of Triune Integrative Medicine in Medford, Oregon. “If you are afraid to go out, experiencing panic attacks, can’t sleep, or your relationships are suffering, you don’t have to live like this. You don’t have to wait. You don’t have to suffer for years. Help is out there – and treatment can help.”

The impact of COVID on anxiety

Many American adults expressed concern regarding how the pandemic has impacted their mental health:

• Second Pandemic. Two in three of all respondents say that the U.S. is experiencing, or will experience, a second pandemic – this time, it will be a mental health pandemic. Almost six in 10 of all respondents said they are concerned with anxiety and/or pandemic-related PTSD.
• Top Causes of Anxiety. “Concern of the safety of loved ones” (68%) and “fear of infection” (57%) were the top reasons cited by all respondents for why the pandemic increased their anxiety symptoms.
• Anxiety Symptoms: Nearly two-thirds of respondents diagnosed with anxiety said their symptoms have increased “a little or a lot” as a result of changing requirements around COVID-19 restrictions.

Mental health conversation is shifting

Of those diagnosed with anxiety, nearly half said they would feel more comfortable talking about their mental health today than they would a year ago.

“The pandemic appears to have made people willing to share their mental health struggles,” said Mark Pollack, MD, chief medical officer for Mental Health at Myriad Genetics. “Talking about mental health challenges is the first step towards getting treatment.”

Mental health disorders should be treated

While more people appear to be willing to talk about their mental health, one out of five respondents still say they won’t seek treatment. The top reasons for those who would NOT seek treatment for a mental challenge are:

• Minimize their struggles. 35% of all respondents say “it’s not a big deal,” while 24% say their struggles are “just a phase.”
• Money. 25% say they didn’t want to spend the money or that it costs too much.
• Medication resistance. 22% say they don’t want to go through trial-and-error medication treatment.

“Untreated anxiety can be associated with distressing and disabling panic attacks, intense worry, and disruption to your life, work and relationships,” said Dr. Pollack. “Like other medical conditions, individuals should seek evaluation and treatment as early as possible, to minimize the distress and dysfunction associated with these conditions.”

Anna, a 32-year-old mother who was first diagnosed with anxiety in her early 20s, said that seeking treatment wasn’t easy. She went through an extensive trial-and-error period with different medications and dosages.

“Medication seems to work fast in my body, so after taking a medication that was supposed to help me, my anxiety would instead get worse – I would have suicidal thoughts and be paralyzed with worry,” said Anna. “My doctor would increase the dosage or change medications, which would lead to horrible side effects.”

Anna then took the GeneSight test, which analyzes how a patient’s genes may affect their outcomes with medications commonly prescribed to treat anxiety, depression, ADHD, and other psychiatric conditions.

“After reviewing the results of my test, my psychiatrist reduced the dose by half, and it helped me. I honestly don’t know if I would have taken another medication if it hadn’t been for genetic testing,” said Anna. “I’m glad I pursued treatment until I found a medication and dosage that worked for me. Now that I’m not riddled with crippling anxiety, everything has gotten better. I’m a better mom. I’m more motivated, more outgoing and friendly.”

For more information on how genetic testing can help inform clinicians on treatment of depression, anxiety, ADHD, and other psychiatric conditions, please visit GeneSight.com. To download graphics, a multimedia video and other information regarding the survey, please visit https://bit.ly/2Y4qGri.

About the GeneSight^® Mental Health Monitor

The GeneSight Mental Health Monitor is a nationwide survey of U.S. adults conducted by ACUPOLL Precision Research, Inc. in Aug.-Sept. 2021 among a statistically representative sample of adults age 21+, including a representative sample diagnosed with anxiety. The margin of error in survey results for the total base population at a 95% confidence interval is +/- 3%.

About the GeneSight^®Test

The GeneSight Psychotropic test from Myriad Genetics is the category-leading pharmacogenomic test for 64 medications commonly prescribed for depression, anxiety, ADHD, and other psychiatric conditions. The GeneSight test can help inform clinicians about how a patient’s genes may impact how they metabolize and/or respond to certain psychiatric medications. It has been given to more than 1.5 million patients by tens of thousands of clinicians to provide genetic information that is unique to each patient. The GeneSight test supplements other information considered by a clinician as part of a comprehensive medical assessment. Learn more at GeneSight.com.

About Myriad Genetics

Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and wellbeing for all, empowering individuals with vital genetic insights and enabling healthcare providers to better detect, treat and prevent disease. Myriad discovers and commercializes genetic tests that determine the risk of developing disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where critical genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit the company’s website: www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, Vectra, EndoPredict, Prequel, Foresight, GeneSight, riskScore and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries.